Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Rituximab Maintenance in MCL Post-AHCT
NCT01267812Phase 2Completed
- Sponsor
- City of Hope
- Start
- Oct 2011
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and rituximab in mantle cell lymphoma (MCL), sponsored by City of Hope. Primary endpoint: Two-year Disease-free Survival at 2 years. Started Oct 2011; status: completed.
02
Drugs
bortezomibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01267812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01267812.